The facts on one page
What is changing for GLP-1 coverage on January 1, 2027, why the Medical Trust says it is necessary, what its own reports show, and what it means for members. Every figure is sourced.
Facts checked on October 24, 2026. If you find an error, please tell us and we will correct it publicly.
What is changing
- From January 1, 2027, “GLP-1s for weight loss, with or without comorbidities, will not be covered.” Type 2 diabetes treatment stays covered. (2027 Annual Enrollment Guide, page 5)
- CPG’s Annual Enrollment page lists the change for “active employees and early retirees.” It is not listed for retirees on Medicare. (CPG, Annual Enrollment; more in Frequently asked questions)
- Wegovy and Zepbound go on the Medical Trust’s Drug Exclusion List. “No prior authorization or medical necessity requests … will be allowed or approved.” Spending on excluded drugs does “not count towards annual deductibles or out-of-pocket costs.” (Evernorth letter to members, October 2026)
- No transition for people in treatment. Asked whether members currently in treatment would lose coverage, CPG’s senior vice president for benefits policy and design answered: “Yes, they will. It’s for everybody. I hate to say there’s no grandfathering.” (CPG webinar recording, August 13, 2026, about 50:30, auto-captions)
- On November 17, 2026, CPG’s chief operating officer said CPG is “exploring” more transition support for members in treatment and has no answer yet. (What CPG’s leaders said on November 17)
- Replacements offered:
- Digbi Health, a coaching program that “does not prescribe medications,” free for Anthem and Cigna plan members;
- help from Quantum Health in buying directly from the manufacturers, with members “responsible for the full cost.” (2027 Enrollment Guide)
Why the Medical Trust says it is necessary
- Without changes, 2027 rates would have risen 22.5%. Ending this coverage saves $8.9 million, or 3.6 percentage points of that increase. The average increase after all changes is 13.3%. (August 2026 webinar slides; Enrollment Guide)
- Spending on these drugs for weight loss grew from about $1.5 million (2023) to $7.2 million (2025), with “nearly $9 million” projected for 2027. (CPG Connect, September 14, 2026; Enrollment Guide)
- CPG has published what it spends on these drugs, but we have not found a published count of how many members take them for weight loss. Our requests ask it to publish one.
- The Medical Trust reported net losses of $19.4 million in 2025 and $10.7 million in 2024. (Denominational Health Plan 2025 Annual Report)
What the Medical Trust’s own reports also show
- Its managed program slowed the growth in costs. The July 2026 report says EncircleRx cut the cost trend for these drugs “from 148% in 2024 to 62% in 2025” and “is estimated to have generated $3.2 million in savings in 2025,” “positioning the plan ahead of broader market practices.” (DHP 2025 Annual Report)
- These drugs were about 8.5% of net pharmacy spending in 2025. (Same report)
- Members can buy these medicines directly from the manufacturers for about half of what the plan pays for them. In August, CPG’s senior vice president for benefits policy and design said the plan’s “net cost after rebates is twice what the individual can get the direct-to-consumer pricing.” (Webinar recording, about 14:28)
- Until now, the Medical Trust has managed this coverage instead of ending it. In its October 2025 guide to choosing 2026 plans, CPG said the Medical Trust “chose to continue to approve coverage of GLP-1s for certain conditions, including weight loss,” with rules on who qualifies. Since January 1, 2025, members have needed a BMI of 32 or more, or a BMI of 27 with two related health conditions, and must take part in Omada Health’s online healthy-habits program. These are the rules members have now; on January 1, 2027, coverage for weight loss ends instead. Rules like these are one of the middle paths we ask for. (CPG Connect, October 1, 2025; saved copy, May 2026)
How members found out
| When | Who heard |
|---|---|
| June 11, 2026 | Diocesan administrators: “Reassessing GLP-1 coverage for weight loss” listed as an option |
| August 13, 2026 | Administrators: decision announced at a webinar |
| September 14, 2026 | CPG Connect, CPG’s client newsletter, mentions the change. It is posted on cpg.org and emailed to CPG’s mailing list |
| By September 18, 2026 | Employers chose their 2027 plans |
| October 14, 2026 | Annual enrollment email to active members points to “Important Plan Design Changes for 2027” on cpg.org, without naming GLP-1s |
| October 22, 2026 | Members’ individual letters from Evernorth arrive, about ten weeks before the cut |
What the evidence says
- These drugs do more than reduce weight. In people with heart disease and without diabetes, semaglutide cut heart attack, stroke and cardiovascular death by 20% (SELECT trial, NEJM 2023). The FDA has approved Wegovy for this use and for a serious liver disease (MASH), and Zepbound for sleep apnea.
- Stopping reverses most of the benefit. People regain about two-thirds of the lost weight within a year of stopping semaglutide (STEP 1 extension, 2022). Blood pressure, blood sugar and cholesterol are projected back to baseline about 1.4 years after stopping (BMJ 2026;392:e085304).
- They are cost-effective at today’s prices, and prices have fallen. The Institute for Clinical and Economic Review found both semaglutide and tirzepatide cost-effective at current net prices (ICER, December 2025). ICER’s estimate of semaglutide’s net price roughly halved between 2022 and 2025.
- Clergy carry a higher burden. A 2024 Duke meta-analysis estimated clergy obesity at about 47% in 2021, about ten points above other US workers (Obesity Reviews 2024).
What it means for a member
- Self-pay prices (manufacturer prices, October 2026; they can change):
- Wegovy pens: $349 per 28-day box at doses up to 2.4 mg; Wegovy HD (7.2 mg) is $399 (NovoCare Pharmacy).
- Wegovy pills: $149–$299 a month by dose (NovoCare Pharmacy).
- Zepbound: $299–$449 a month by dose, higher if a refill is late (LillyDirect).
- For one person on a maintenance dose, that is roughly $3,600–$5,800 a year. None of it counts toward the deductible or out-of-pocket maximum.
- At $349 per 28-day box, a year of Wegovy pens costs about $4,500, or about 14% of the median part-time clergy salary of about $33,000 (CPG clergy compensation report, 2025).
If you are losing coverage, start with Help if you’re losing coverage. There is more in the evidence library and the frequently asked questions, and our requests are on what we are asking for. Who decides what the Medical Trust covers explains who runs the plan, and Medical Trust rates for 2027 covers the rate increase. If you are holding the letter, see The Evernorth letter about Wegovy and Zepbound; the replacement program is described on Digbi Health and the Medical Trust.
Last updated